TABLE 1

Cannabis Products

Products Generic (Brand)Cannabinoid ContentAdministration Formulation and DosageFDA ApprovalIndicationsApproved Countries
Dronabinol (Marinol and Syndros)Synthetic δ-9-THCOral capsule or solutionApproved in 1985, Schedule III controlled substanceCINV (pediatric and adult), anorexia associated with weight loss in AIDS (adult)United States, Australia, Germany, New Zealand, and South Africa
5–15 mg/m2 per dose, up to 6 doses daily
Nabilone (Cesamet)Synthetic δ-9-THCOral capsuleApproved in 1985, Schedule II controlled substanceCINVUnited States, Canada, Ireland, Mexico, and United Kingdom
1 or 2 mg twice a day, up to 6 mg daily (adult)
Nabiximols (Sativex)Ratio of 2.7 δ-9-THC to 2.5 CBD, plant derivedOromucosal sprayPhase III trialsNeuropathic pain, cancer pain, multiple sclerosis spasticityCanada, Czech Republic, United Kingdom, Denmark, Germany, Poland, Spain, and Sweden
1 spray daily, up to 12 sprays daily with at least 15 min between sprays (adult)
CBD (Epidiolex)CBD, plant derivedOral solutionPhase III trials, fast-track designationEpilepsyNone
2 up to 50 mg/kg per d (research trials)
Cannabis plant products (eg, marijuana and oral cannabis extracts)Varying concentration of plant-derived THC to CBDIncludes smoking (marijuana) and oral (cannabis extracts)None, Schedule I controlled substanceNone approvedMedically and recreationally legal in certain states via physician certification